One2Treat

🌟 Welcome, Tom Mann!  We are excited to announce that Tom has joined the One2Treat team as our new 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐄𝐧𝐠𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐋𝐞𝐚𝐝! 🎉 Tom brings over 15 years of experience in tech start-ups and scale-ups where he was instrumental in driving a wide range of customer engagement and marketing initiatives. His expertise in #SaaS companies and fresh perspective will be invaluable as we continue to develop solutions to integrate key patient-relevant outcomes into a holistic treatment assessment. Join us in welcoming Tom to the One2Treat team! We look forward to achieving great things together, moving toward patient-focused clinical research. 🚀  #Welcome #ClinicalTrials #PatientCentricity #DigitalInnovation #WorkingWithPurpose 

Revisit the story behind One2Treat's journey "from frustration to innovation". Our founder, Marc Buyse, reflects on the pivotal moments that inspired him to create One2Treat. Driven by the need for a more patient-centric approach, Marc founded One2Treat to empower the biopharma industry to prioritize patient needs at every step. By enabling the comprehensive analysis of treatment effects across multiple clinically relevant criteria, One2Treat offers a fuller picture of a treatment's potential benefits and risks.   Read Marc's insights and learn how One2Treat is shaping the future of medical research : https://lnkd.in/e5XZc2Jm #PatientCentricity #ClinicalInnovation #TreatmentDecisions #WorkWithPurpose

Sébastien Coppe, PhD, One2Treat's CEO, recently shared his insights on the future of AI in the pharmaceutical industry in an piece with Outsourcing-Pharma.   Discover how AI can create new opportunities in clinical trials, inform patient-centric trial designs, and drive innovation in drug development over the next five years.   Read the full interview here: https://lnkd.in/epsH-5E2   #AI #ClinicalTrials #Innovation #PatientCentricity

One2Treat expert Jean-Christophe Chiêm, PhD was invited to speak on Monday for an insightful and interactive webinar hosted by the Institute of Clinical Trials and Methodology at UCL & MRC Clinical Trials Unit at UCL   Jean-Christophe discussed the challenges of non-inferiority clinical trials, such as the large sample size required to demonstrate it. What if it were possible to show superiority of the benefits risk profile of the treatment instead ? Jean-Christophe showed how it is possible to integrate multiple outcomes into a single assessment. This approach leads to significant sample size reduction and improves the evaluation process by transforming non-inferiority trials into more patient-relevant superiority assessments.   Thanks again, Institute of Clinical Trials and Methodology at UCL & MRC Clinical Trials Unit at UCL, for the invitation and fruitful discussion! Want to learn more about our innovative approach to clinical trials? Don't forget to follow our LinkedIn page and visit our website. #NItrials #MultipleOutcomes #SampleSizeReduction #PatientCentricity #ClinicalResearch

We are delighted to welcome Pascal Piedbois at One2Treat as our Chief Medical Officer. Pascal Piedbois, Prof. of Medical Oncology, brings over 30 years of clinical development experience in both academia and industry, holding positions including Head of Medical Oncology at Paris University, General Director of the Comprehensive Cancer Center of Alsace Region, and several leadership roles in the pharmaceutical industry, including Vice President, Head of Global Oncology and Infectious Diseases at AstraZeneca, Senior Vice President, Medical Head Major Markets at Bristol Myers Squibb and General Manager at Boehringer Ingelheim Belgium. Our Founder, Marc Buyse, emphasizes the importance of a patient-centric approach in clinical research: "Pascal's medical expertise will speed up the implementation of this multi-dimensional approach, ensuring our message resonates with medical leaders.” Sébastien Coppe, CEO of One2Treat, adds: "Pascal’s extensive experience and strategic insights will be crucial in driving forward our mission to transform clinical trial design and market access. We are excited to see the impact his leadership will bring." Welcome to Pascal Piedbois to the One2Treat family and stay tuned as we continue to push the boundaries of clinical research to improve patient outcomes. Read the full press release here: https://lnkd.in/evG8NYKG   #PatientCentricity #ClinicalTrials #Innovation

I will be honoured to talk at the ICTM webinar this Monday 8th july organized by Institute of Clinical Trials and Methodology at UCL and MRC Clinical Trials Unit at UCL   I will address issues of non-inferiority #NItrials which are often impractical and pose several challenges compared to superiority trials. Our statistical method of generalized pairwise comparison (#GPC) can tackle some of these issues by allowing the simultaneous evaluation of #multipleoutcomes of interest, adopting an adequate #prioritization according to their perceived clinical importance. This solution has led us to drastic #samplesize #reduction and a formulation of the research questions promoting #patientcentricity, as detailed in this case study.

Don't miss the insightful article on the #SHAPERS trial from Institut Jules Bordet, which enrolled its first patient a month ago, published this week in ESMO - European Society for Medical Oncology journal "Gastrointestinal Oncology". The SHAPERS trial evaluates the efficacy and safety of short-course radiotherapy (SCRT) versus total neoadjuvant therapy (TNT) in older rectal cancer patients. In a groundbreaking shift, the trial was designed by Institut Jules Bordet and One2Treat Teams, leveraging the Generalized Pairwise Comparisons method (#GPC), allowing to move from a non-inferiority framework to a superiority trial, tremendously reducing the required sample size. This innovative approach leverages GPC to compute the Net Treatment Benefit of the treatment to assess overall survival, progression-free survival, and treatment-related toxicities in a single endpoint. Dive into the details and discover how this study is setting new standards in the treatment of older rectal cancer patients: https://lnkd.in/ebQwDPmK #ClinicalTrials #Oncology #PatientCentricity #Innovation

Check out our latest Q&A published in Contract Pharma, where One2Treat’s CEO, Sébastien Coppe, PhD, shares his expertise on the evolving landscape of clinical research and its pivotal role supporting sponsor's needs.   💡 Patient-centricity in clinical trials is becoming a critical focus, with an emphasis on integrating patient perspectives from trial design to market access. 💡 Innovative statistical methodologies are revolutionizing clinical trials, enhancing patient-centricity and improving trial efficiency. 💡 The increasing complexity of clinical trials and evolving regulatory landscapes open new opportunities for digital innovation, allowing to align multiple important stakeholders (patients, sponsor, regulatory agencies and payers) as early as clinical trial design.   Read the full Q&A to learn how One2Treat is leading the way in transforming clinical trials with a patient-centered approach. 👉 https://lnkd.in/eiPxqDjG #ClinicalTrials #PatientCentricity #Innovation

Join us at One2Treat! Are you passionate about driving innovation in clinical research? We're seeking talented biostatisticians to join us in transforming patient care. Senior Trial Design Lead Biostatistician: Calling all expert biostatisticians PhD holders with prior experience in clinical trial design and a drive for innovation. Let's design clinical trials that will shape the future of patient care, incorporating multiple criteria (e.g. quality of life) within a single treatment's effects assessment in the primary analysis of trial designs. Ready to make a difference? You share One2Treat core values, want to join us on our mission and make a concrete impact on future patients care? Visit our careers page to learn more and apply today: https://lnkd.in/gzMgSvkj #Hiring #HealthcareInnovation #WorkWithPurpose

We are happy to welcome Rudradev Sengupta at One2Treat. After his PhD thesis on "Surrogacy and Biomarker Detection" at Hasselt University, Rudradev applied his statistical modeling and programming expertise for 6 years at Johnson & Johnson. With a passion for innovation, he is set to bring a fresh perspective to our mission of revolutionizing patient-centric clinical trials. At One2Treat, we are committed to pushing the boundaries of clinical research, ensuring that every trial we design is not only scientifically robust but also truly patient-centered. With Rudradev on board, we are excited to take our projects to new heights and continue driving advancements in the field of clinical trials. Join us in giving Rudradev a warm welcome! We're excited to see the incredible contributions you'll make and the impact we'll achieve together. Stay tuned to our page as we just opened a new position for an experienced trial design biostatistician : https://lnkd.in/gzMgSvkj #Welcome #ClinicalTrials #PatientCentricity #DigitalInnovation #WorkingWIthPurpose